Literature DB >> 19553103

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

M Mandalà1, G L Imberti, D Piazzalunga, M Belfiglio, R Labianca, M Barberis, L Marchesi, P Poletti, L Bonomi, L Novellino, K Di Biagio, A Milesi, U Guerra, C Tondini.   

Abstract

BACKGROUND: To investigate if the tumour infiltrating lymphocytes (TILs) are able to predict the sentinel lymph node (SLN) positivity, the disease-free survival (DFS) and overall survival (OS) in clinical stages I-II AJCC primary cutaneous melanoma (PCM).
METHODS: The study included consecutive patients with PCM, all diagnosed, treated and followed up prospectively. Logistic regression was used to investigate the association between DFS, OS, SLN positivity and Breslow thickness, Clark level, TIL, ulceration, lesion site, gender, regression and age.
RESULTS: From November 1998 to October 2008, 1251 consecutive patients with PCM were evaluated. Median age was 51 (range 15-96) with 32.2% (N=393) of them older than 60; 44.8% of them were males. Of the whole series, a total of 404 patients with primary vertical growth phase (VGP) melanoma and no clinical evidence of metastatic disease underwent SLN biopsy. Of these, 74 (18.8%) had a positive SLN. In a multivariate analysis, primary melanoma on the extremities versus that on the axial locations (truncal and head/neck) (OR 0.49, 95% CI 0.25-0.98, p 0.04) and TILs (TILs versus no TILs) (OR 0.47, 95%CI 0.25-0.90, p 0.02) were predictive for lower probability of SLN involvement, while thickness (>4mm versus 0-1mm) (OR 24, 19, 95% CI 4.91-119.13, p<.001) was predictive for higher risk of SLN positivity. A multivariate stepwise analysis confirmed these results. The histological status of the SLN was the most significant predictor of DFS and OS. Patients with a negative SLN had a 5-year DFS of 75.9%, compared with 35.2% in patients with a positive SLN (p<.0001) and a 5-year OS of 88.7% versus 42.9%, respectively (p<.0001).
CONCLUSIONS: Our study demonstrates that the absence of TILs predicts SLN metastasis, in multivariate analysis the SLN positivity predicts DFS and OS.

Entities:  

Mesh:

Year:  2009        PMID: 19553103     DOI: 10.1016/j.ejca.2009.05.034

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  30 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma.

Authors:  Mario Mandalà; Gian Lorenzo Imberti; Dario Piazzalunga; Maurizio Belfiglio; Giuseppe Lucisano; Roberto Labianca; Lorenzo Marchesi; Barbara Merelli; Silvana Robone; Paola Poletti; Laura Milesi; Carlo Tondini
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

3.  Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Authors:  Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

4.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

5.  Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node.

Authors:  Michelle W Ma; Ratna C Medicherla; Meng Qian; Eleazar Vega-Saenz de Miera; Erica B Friedman; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Patrick A Ott; Nina Bhardwaj; Yongzhao Shao; Iman Osman; Farbod Darvishian
Journal:  Mod Pathol       Date:  2012-03-16       Impact factor: 7.842

6.  Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Authors:  Sarah A Weiss; Sung Won Han; Kevin Lui; Jeremy Tchack; Richard Shapiro; Russell Berman; Judy Zhong; Michelle Krogsgaard; Iman Osman; Farbod Darvishian
Journal:  Hum Pathol       Date:  2016-07-26       Impact factor: 3.466

7.  Multiple lymphatic basin drainage from cutaneous melanoma as a prognostic factor.

Authors:  Antonio Piñero; Carlos de Torre; Jorge Martínez-Escribano; Juana Campillo; Manuel Canteras; Francisco Nicolás
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

8.  Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution.

Authors:  Torsten Hinz; Hojjat Ahmadzadehfar; Anja Wierzbicki; Tobias Hoeller; Joerg Wenzel; Hans-J Biersack; Thomas Bieber; Monika-H Schmid-Wendtner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-23       Impact factor: 9.236

9.  Validation of statistical predictive models meant to select melanoma patients for sentinel lymph node biopsy.

Authors:  Michael S Sabel; John D Rice; Kent A Griffith; Lori Lowe; Sandra L Wong; Alfred E Chang; Timothy M Johnson; Jeremy M G Taylor
Journal:  Ann Surg Oncol       Date:  2011-08-06       Impact factor: 5.344

10.  Association Between Patient Age and Lymph Node Positivity in Thin Melanoma.

Authors:  Andrew J Sinnamon; Madalyn G Neuwirth; Pratyusha Yalamanchi; Phyllis Gimotty; David E Elder; Xiaowei Xu; Rachel R Kelz; Robert E Roses; Emily Y Chu; Michael E Ming; Douglas L Fraker; Giorgos C Karakousis
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.